Dicerna to Present at Three Upcoming Investor Conferences
.LaVoie Health ScienceDonna LaVoie or Maureen Brown, 617-374-8800orDicerna PharmaceuticalsMichele Rozen, 617-953-2214
(NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, PhD, President and CEO, will present at three upcoming conferences, including the 2014 Leerink Rare Disease Roundtable, Bernstein’s Genes as Drugs Event, and the 13 Annual BIO Investor Forum. In addition to the corporate update presentation at Bernstein’s event, Dr. Fambrough will participate in a panel with other industry leaders.
October 1, 2014Le Parker Meridien, New York10:40- 11:00 AM ETTansa Room
October 7, 2014Presentation at 10:15 AM ETPanel at 11:00 AM ET
October 8, 2014The Palace Hotel, San Francisco10:00 – 10:25 AM PTPresidio Room
A webcast of the presentation can be accessed by visiting “” in the Investors and Media section on the Company’s website at for the 2014 Leerink Rare Disease Roundtable. An archived replay of the webcast will be available on the Company’s website after the conference.
Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare, inherited diseases involving the liver and for cancers that are genetically defined. The Company is using its proprietary RNA interference (RNAi) technology platform to build a broad pipeline in these therapeutic areas. In both rare diseases and oncology, Dicerna is pursuing targets that have historically been difficult to inhibit using conventional approaches, but where connections between targets and diseases are well understood and documented. The Company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit .